Baseline characteristics according to diagnosis at inclusion (n=10 517 patients)
| CAD alone (n=4303) | AF alone (n=2604) | CAD+AF (n=700) | HF alone (n=513) | HF+CAD (n=728) | HF+AF (n=1087) | HF+CAD+AF (n=582) | All CAD (n=6313) | All AF (n=4973) | All HF (n=2910) | |
| Age, years | 66±11 | 71±11 | 74±10 | 65±14 | 69±13 | 74±12 | 76±10 | 68±12 | 73±11 | 72±13 |
| Women | 22 | 49 | 27 | 42 | 26 | 51 | 27 | 23 | 44 | 38 |
| History of hypertension | 59 | 64 | 72 | 47 | 61 | 64 | 71 | 62 | 66 | 62 |
| History of diabetes mellitus | 30 | 19 | 29 | 27 | 39 | 25 | 39 | 32 | 24 | 32 |
| Previous stroke | 4 | 8 | 10 | 5 | 8 | 7 | 11 | 6 | 8 | 8 |
| History of PAD | 23 | 9 | 23 | 10 | 26 | 8 | 25 | 23 | 12 | 16 |
| Patients with CAD | ||||||||||
| Previous myocardial infarction | 48 | – | 38 | – | 65 | – | 49 | 49 | – | – |
| Previous percutaneous coronary intervention | 74 | – | 62 | – | 66 | – | 55 | 70 | – | – |
| Previous coronary bypass | 19 | – | 27 | – | 21 | – | 29 | 21 | – | – |
| Patients with AF | ||||||||||
| First-diagnosed | – | 7 | 6 | – | – | 4 | 4 | – | 6 | – |
| Paroxysmal | – | 42 | 44 | – | – | 22 | 24 | – | 36 | – |
| Persistent | – | 19 | 18 | – | – | 22 | 21 | – | 20 | – |
| Permanent | – | 32 | 32 | – | – | 52 | 51 | – | 38 | – |
| Non-valvular | – | 92 | 93 | – | – | 83 | 90 | – | 90 | – |
| Mean CHA2DS2-VASc score | – | 2.8±1.5 | 3.9±1.3 | – | – | 4.0±1.6 | 5.1±1.4 | – | 3.4±1.7 | – |
| Patients with HF | ||||||||||
| NYHA class 3–4 | – | – | – | 16 | 20 | 24 | 31 | – | – | 23 |
| LVEF | ||||||||||
| Mean, % | – | – | – | 46±13 | 43±12 | 53±13 | 45±14 | – | – | 48±13 |
| <40% | – | – | – | 29 | 35 | 15 | 32 | – | – | 26 |
| 40%–49% | – | – | – | 28 | 31 | 16 | 25 | – | – | 24 |
| ≥50% | – | – | – | 43 | 34 | 69 | 43 | – | – | 50 |
| Prior implantable cardioverter defibrillator | – | – | – | 13 | 20 | 6 | 15 | – | – | 13 |
| Medications at inclusion | ||||||||||
| Antiplatelet drug | 98 | 16 | 62 | 45 | 95 | 10 | 53 | 90 | 26 | 46 |
| Statin | 93 | 40 | 86 | 45 | 90 | 41 | 84 | 91 | 52 | 62 |
| ACE-I or ARB | 82 | 55 | 78 | 90 | 91 | 73 | 84 | 83 | 65 | 83 |
| Beta-blocker | 81 | 62 | 77 | 84 | 91 | 77 | 85 | 82 | 70 | 83 |
| Vitamin K antagonist | 3 | 50 | 54 | 10 | 10 | 69 | 72 | 16 | 57 | 44 |
| Direct oral anticoagulant | <1 | 26 | 17 | <1 | <1 | 19 | 13 | 3 | 22 | 10 |
| Amiodarone | <1 | 17 | 22 | 2 | 4 | 28 | 25 | 6 | 21 | 17 |
| Digoxin | <1 | 9 | 4 | 3 | <1 | 15 | 7 | 1 | 9 | 8 |
| Mineralocorticoid receptor antagonist | 4 | 3 | 4 | 27 | 32 | 14 | 21 | 9 | 8 | 22 |
| Diuretic | 22 | 35 | 39 | 64 | 65 | 78 | 82 | 34 | 50 | 73 |
Data are presented as mean±SD or percentage.
ACE-I, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAD, peripheral artery disease.